9BIG
| Stat6 bound to degrader AK-1690 | Descriptor: | Signal transducer and activator of transcription 6, [(2-{[(2S)-1-{(2S,4S)-4-[(7-{2-[(3R)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-4-yl}hept-6-yn-1-yl)oxy]-2-[(2R)-2-phenylmorpholine-4-carbonyl]pyrrolidin-1-yl}-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}-1-benzothiophen-5-yl)di(fluoro)methyl]phosphonic acid | Authors: | Mallik, L, Stuckey, J.A. | Deposit date: | 2024-04-23 | Release date: | 2024-10-02 | Method: | X-RAY DIFFRACTION (3.304 Å) | Cite: | Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC Degrader. J.Med.Chem., 2024
|
|
9BIK
| Crystal structure of inhibitor 1 bound to HPK1 | Descriptor: | (1S,2S)-N-[(6P)-8-amino-6-(4-methylpyridin-3-yl)isoquinolin-3-yl]-2-cyanocyclopropane-1-carboxamide, 1,2-ETHANEDIOL, Mitogen-activated protein kinase kinase kinase kinase 1 | Authors: | Kiefer, J.T, Tellis, J.C, Chan, B.K, Wang, W, Wu, P, Siu, M, Heffron, T.P, Choo, E.F. | Deposit date: | 2024-04-23 | Release date: | 2024-10-02 | Method: | X-RAY DIFFRACTION (2.25 Å) | Cite: | Discovery of GNE-6893, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of HPK1. Acs Med.Chem.Lett., 15, 2024
|
|
9BIO
| |
9BIR
| Cryo-EM structure of the mammalian peptide transporter PepT2 bound to cefadroxil | Descriptor: | Cefadroxil, Solute carrier family 15 member 2, nanobody | Authors: | Parker, J.L, Deme, J.C, Lea, S.M, Newstead, S. | Deposit date: | 2024-04-24 | Release date: | 2024-07-24 | Last modified: | 2024-10-30 | Method: | ELECTRON MICROSCOPY (3.1 Å) | Cite: | Structural basis for antibiotic transport and inhibition in PepT2. Nat Commun, 15, 2024
|
|
9BJ1
| Crystal structure of inhibitor GNE-6893 bound to HPK1 | Descriptor: | (4S,5R,7R,11aP)-10-{[(3R)-3-hydroxy-1-methyl-2-oxopyrrolidin-3-yl]ethynyl}-N~3~-methyl-6,7-dihydro-5H-5,7-methanoimidazo[2,1-a][2]benzazepine-2,3-dicarboxamide, (9S)-2-{[(6P)-8-amino-6-(5-amino-4-methylpyridin-3-yl)-7-fluoroisoquinolin-3-yl]amino}-6-methyl-5,6-dihydro-4H-pyrazolo[1,5-d][1,4]diazepin-7(8H)-one, 1,2-ETHANEDIOL, ... | Authors: | Kiefer, J.R, Tellis, J.C, Chan, B.K, Wang, W, Wu, P, Choo, E.F, Heffron, T.P, Wei, B, Siu, M. | Deposit date: | 2024-04-24 | Release date: | 2024-10-02 | Method: | X-RAY DIFFRACTION (2.18 Å) | Cite: | Discovery of GNE-6893, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of HPK1. Acs Med.Chem.Lett., 15, 2024
|
|
9BJK
| Inactive mu opioid receptor bound to Nb6, naloxone and NAM | Descriptor: | Mu-type opioid receptor, Naloxone, Nalpha-[({(1M)-1-[5-(benzyloxy)pyridin-3-yl]naphthalen-2-yl}sulfanyl)acetyl]-3-methoxy-N,4-dimethyl-L-phenylalaninamide, ... | Authors: | O'Brien, E.S, Wang, H, Kaavya Krishna, K, Zhang, C, Kobilka, B.K. | Deposit date: | 2024-04-25 | Release date: | 2024-07-17 | Last modified: | 2024-11-13 | Method: | ELECTRON MICROSCOPY (3.26 Å) | Cite: | A mu-opioid receptor modulator that works cooperatively with naloxone. Nature, 631, 2024
|
|
9BJM
| Crystal Structure of Inhibitor 5c in Complex with Prefusion RSV F Glycoprotein | Descriptor: | 1'-{[5-chloro-1-(4,4,4-trifluorobutyl)-1H-1,3-benzimidazol-2-yl]methyl}-1-(methanesulfonyl)spiro[azetidine-3,3'-indol]-2'(1'H)-one, Prefusion RSV F (DS-CAV1),Envelope glycoprotein | Authors: | Shaffer, P.L, Milligan, C, Abeywickrema, P. | Deposit date: | 2024-04-25 | Release date: | 2024-07-10 | Last modified: | 2024-07-24 | Method: | X-RAY DIFFRACTION (2.07 Å) | Cite: | Spiro-Azetidine Oxindoles as Long-Acting Injectables for Pre-Exposure Prophylaxis against Respiratory Syncytial Virus Infections. J.Med.Chem., 67, 2024
|
|
9BJN
| Cryo-EM of Azo-ffspy fiber | Descriptor: | D-peptide ffspy | Authors: | Zia, A, Guo, J, Xu, B, Wang, F. | Deposit date: | 2024-04-25 | Release date: | 2024-09-18 | Last modified: | 2024-10-02 | Method: | ELECTRON MICROSCOPY (3 Å) | Cite: | Cell-Free Nonequilibrium Assembly for Hierarchical Protein/Peptide Nanopillars. J.Am.Chem.Soc., 146, 2024
|
|
9BJO
| Cryo-EM of Azo-ffsy fiber | Descriptor: | D-peptide ffsy | Authors: | Zia, A, Guo, J, Xu, B, Wang, F. | Deposit date: | 2024-04-25 | Release date: | 2024-09-18 | Last modified: | 2024-10-23 | Method: | ELECTRON MICROSCOPY (2.8 Å) | Cite: | Cell-Free Nonequilibrium Assembly for Hierarchical Protein/Peptide Nanopillars. J.Am.Chem.Soc., 146, 2024
|
|
9BJU
| Crystal structure of the complex between VHL, ElonginB, ElonginC, and compound 5 | Descriptor: | 1,2-ETHANEDIOL, 3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.]PYRAZOLE, ACETATE ION, ... | Authors: | Murray, J.M, Wu, H, Fuhrmann, J, Fairbrother, W.J, DiPasquale, A. | Deposit date: | 2024-04-25 | Release date: | 2024-05-29 | Last modified: | 2024-10-16 | Method: | X-RAY DIFFRACTION (2.47 Å) | Cite: | Potency-Enhanced Peptidomimetic VHL Ligands with Improved Oral Bioavailability. J.Med.Chem., 67, 2024
|
|
9BK2
| Crystal structure of Lactate dehydrogenase in complex with 4-((4-(1-methyl-1H-imidazole-2-carbonyl)phenyl)amino)-4-oxo-2-(4-(trifluoromethyl)phenyl)butanoic acid (S-enantiomer, monoclinic P form) | Descriptor: | (2S)-4-[4-(1-methyl-1H-imidazole-2-carbonyl)anilino]-4-oxo-2-[4-(trifluoromethyl)phenyl]butanoic acid, DIMETHYL SULFOXIDE, L-lactate dehydrogenase A chain, ... | Authors: | Lovell, S, Cooper, A, Battaile, K.P, Sharma, H. | Deposit date: | 2024-04-26 | Release date: | 2024-07-10 | Last modified: | 2024-09-04 | Method: | X-RAY DIFFRACTION (1.85 Å) | Cite: | Synthesis and biological characterization of an orally bioavailable lactate dehydrogenase-A inhibitor against pancreatic cancer. Eur.J.Med.Chem., 275, 2024
|
|
9BK3
| Crystal structure of Lactate dehydrogenase in complex with 4-((4-(1-methyl-1H-imidazole-2-carbonyl)phenyl)amino)-4-oxo-2-(4-(trifluoromethyl)phenyl)butanoic acid (R-enantiomer, orthorhombic P form) | Descriptor: | (2R)-4-[4-(1-methyl-1H-imidazole-2-carbonyl)anilino]-4-oxo-2-[4-(trifluoromethyl)phenyl]butanoic acid, CHLORIDE ION, L-lactate dehydrogenase A chain, ... | Authors: | Lovell, S, Cooper, A, Battaile, K.P, Sharma, H. | Deposit date: | 2024-04-26 | Release date: | 2024-07-10 | Method: | X-RAY DIFFRACTION (2.4 Å) | Cite: | Synthesis and biological characterization of an orally bioavailable lactate dehydrogenase-A inhibitor against pancreatic cancer. Eur.J.Med.Chem., 275, 2024
|
|
9BKM
| DHODH in complex with Ligand 10 | Descriptor: | (2M,6P)-2-(2-chloro-6-fluorophenyl)-6-[4-ethyl-3-(hydroxymethyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-7-fluoro-4-(propan-2-yl)isoquinolin-1(2H)-one, ACETATE ION, Dihydroorotate dehydrogenase (quinone), ... | Authors: | Shaffer, P.L. | Deposit date: | 2024-04-29 | Release date: | 2024-07-03 | Last modified: | 2024-07-24 | Method: | X-RAY DIFFRACTION (2.08 Å) | Cite: | Discovery of JNJ-74856665: A Novel Isoquinolinone DHODH Inhibitor for the Treatment of AML. J.Med.Chem., 67, 2024
|
|
9BKN
| DHODH in complex with Ligand 16 | Descriptor: | (2P,6P)-6-[4-ethyl-3-(hydroxymethyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-7-fluoro-2-(2-methylphenyl)-4-(propan-2-yl)isoquinolin-1(2H)-one, ACETATE ION, CHLORIDE ION, ... | Authors: | Shaffer, P.L. | Deposit date: | 2024-04-29 | Release date: | 2024-07-03 | Last modified: | 2024-07-24 | Method: | X-RAY DIFFRACTION (1.3 Å) | Cite: | Discovery of JNJ-74856665: A Novel Isoquinolinone DHODH Inhibitor for the Treatment of AML. J.Med.Chem., 67, 2024
|
|
9BKO
| DHODH in complex with Ligand 26 | Descriptor: | (2P,6P)-6-[4-ethyl-3-(hydroxymethyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-7-fluoro-2-(2-methylphenyl)-4-[(2R)-1,1,1-trifluoropropan-2-yl]isoquinolin-1(2H)-one, ACETATE ION, CHLORIDE ION, ... | Authors: | Shaffer, P.L. | Deposit date: | 2024-04-29 | Release date: | 2024-07-03 | Last modified: | 2024-07-24 | Method: | X-RAY DIFFRACTION (1.44 Å) | Cite: | Discovery of JNJ-74856665: A Novel Isoquinolinone DHODH Inhibitor for the Treatment of AML. J.Med.Chem., 67, 2024
|
|
9BKQ
| Structure of penguinpox cGAMP PDE in apo and post reaction states | Descriptor: | 9-{3-O-[(S)-thiophosphono]-alpha-L-lyxofuranosyl}-9H-purin-6-amine, GUANINE, Penguinpox cGAMP PDE | Authors: | Hobbs, S.J, Nomburg, J, Doudna, J.A, Kranzusch, P.J. | Deposit date: | 2024-04-29 | Release date: | 2024-09-04 | Last modified: | 2024-10-16 | Method: | X-RAY DIFFRACTION (2.1 Å) | Cite: | Animal and bacterial viruses share conserved mechanisms of immune evasion. Cell, 187, 2024
|
|
9BL4
| |
9BLG
| Crystal structure of non-receptor protein tyrosine phosphatase SHP2 in complex with PF-07284892 | Descriptor: | (1S)-1'-{6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-1,2,4-triazin-3-yl}-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine, Tyrosine-protein phosphatase non-receptor type 11 | Authors: | Bester, S.M, Wu, W.-I, Mou, T.-C. | Deposit date: | 2024-04-30 | Release date: | 2024-05-29 | Method: | X-RAY DIFFRACTION (2.06 Å) | Cite: | SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy. Cancer Discov, 13, 2023
|
|
9BLN
| The structure of human Pdcd4 bound to the 40S-eIF4A-eIF3-eIF1 complex | Descriptor: | 40S ribosomal protein S14, ACETIC ACID, Eukaryotic initiation factor 4A-I, ... | Authors: | Brito Querido, J, Sokabe, M, Diaz-Lopez, I, Gordiyenko, Y, Zuber, P, Yifei, D, Albacete-Albacete, L, Ramakrishnan, V, S Fraser, C. | Deposit date: | 2024-04-30 | Release date: | 2024-09-04 | Last modified: | 2024-10-09 | Method: | ELECTRON MICROSCOPY (3.9 Å) | Cite: | Human tumor suppressor protein Pdcd4 binds at the mRNA entry channel in the 40S small ribosomal subunit. Nat Commun, 15, 2024
|
|
9BN8
| |
9BN9
| |
9BNQ
| N-(4-(isothiocyanatomethyl)phenyl)methanesulfonamide complexed with Macrophage Migration Inhibitory Factor | Descriptor: | ISOPROPYL ALCOHOL, Macrophage migration inhibitory factor, N-{[4-(methanesulfonamido)phenyl]methyl}methanethioamide, ... | Authors: | Fellner, M, Rutledge, M.T, Putha, L, Kok, L.K, Gamble, A.B, Wilbanks, S.M, Vernall, A.J, Tyndall, J.D.A. | Deposit date: | 2024-05-02 | Release date: | 2024-07-24 | Last modified: | 2024-11-13 | Method: | X-RAY DIFFRACTION (1.09 Å) | Cite: | Covalent isothiocyanate inhibitors of macrophage migration inhibitory factor as potential colorectal cancer treatments. Chemmedchem, 2024
|
|
9BNR
| 4-(2-isothiocyanatoethyl)benzenesulfonamide complexed with Macrophage Migration Inhibitory Factor | Descriptor: | Macrophage migration inhibitory factor, N-[2-(4-sulfamoylphenyl)ethyl]methanethioamide, SULFATE ION | Authors: | Fellner, M, Rutledge, M.T, Putha, L, Kok, L.K, Gamble, A.B, Wilbanks, S.M, Vernall, A.J, Tyndall, J.D.A. | Deposit date: | 2024-05-02 | Release date: | 2024-07-24 | Last modified: | 2024-11-06 | Method: | X-RAY DIFFRACTION (1.53 Å) | Cite: | Covalent isothiocyanate inhibitors of macrophage migration inhibitory factor as potential colorectal cancer treatments. Chemmedchem, 2024
|
|
9BOH
| Room-temperature X-ray structure of Thermus Thermophilus serine hydroxymethyltransferase (SHMT) with PLP-glycine external aldimine and 5-formyltetrahydrofolate (folinic acid) | Descriptor: | (E)-N-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methylidene)glycine, N-[4-({[(6S)-2-amino-5-formyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid, SULFATE ION, ... | Authors: | Drago, V.N, Kovalevsky, A. | Deposit date: | 2024-05-03 | Release date: | 2024-08-28 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | Universality of critical active site glutamate as an acid-base catalyst in serine hydroxymethyltransferase function. Chem Sci, 15, 2024
|
|
9BOL
| Crystal structure of the complex between VHL, ElonginB, ElonginC, and compound 5 | Descriptor: | (4R)-1-[(2S)-2-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}-L-prolinamide, 1,2-ETHANEDIOL, CHLORIDE ION, ... | Authors: | Murray, J.M, Wu, H, Fuhrmann, J, Fairbrother, W.J, DiPasquale, A. | Deposit date: | 2024-05-03 | Release date: | 2024-05-29 | Last modified: | 2024-10-16 | Method: | X-RAY DIFFRACTION (1.99 Å) | Cite: | Potency-Enhanced Peptidomimetic VHL Ligands with Improved Oral Bioavailability. J.Med.Chem., 67, 2024
|
|